No insider purchase over the last 90 days. The latest, by 한대희, was filed 12 May 2026.
PharmGen Science, Inc.: what insiders have been doing
PharmGen Science, Inc. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Between 22 October 2025 and 22 October 2026, 6 insiders published 8 filings.
On the market, 4 insiders bought (4 purchases totalling €1.7M) while 2 insiders sold (2 sales). The totals exclude 5 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 2 senior executives and 1 board member. 한대희 filed the largest purchase, €1.7M, on 12 May 2026, which represents 4.3% of the company's market value.
For context, the typical company on the same exchange (median of 2,650 companies) published 7 filings over the same period, against 8 filings here. Over the whole record (from 2021), the tally stands at 74 purchases and 3 sales.
The last insider purchase was made public on 12 May 2026, 181 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 4 days. This delay matters because a trade only becomes useful information once it is public.
Other companies in the same sector with recent insider buying flagged by our signals: UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySale+2 other insiders
Since the insiders bought
- -27.8%Entry ₩3,850 · Close 21 Oct 2026 ₩2,780
- -34.0%Entry ₩4,210 · Close 21 Oct 2026 ₩2,780
- +1.6%Entry ₩4,090 · Close at T+365 ₩4,155
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 17,869 sharesKRXDART:20260512000579
- 807,537 shares@ ₩3,715.004.35% mcap100.0% of flowShareKRXDART:20260512000599Canonical exit: 9 Aug 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- 4,620,307 sharesKRXDART:20251218000390Canonical exit: 11 Mar 2026 (T+90)
- 3,038 sharesShareKRXDART:20251218000378Canonical exit: 18 Mar 2026 (T+90)
- 4,620,307 sharesKRXDART:20251218000345
- Other0DART
- Other0DART
- 25,707 sharesShareKRXDART:20251218000363Canonical exit: 18 Mar 2026 (T+90)
- 2,114,172 sharesKRXDART:20250410002495
- ●Executives0DART
- 220,845 sharesKRXDART:20241211000448Canonical exit: 11 Mar 2025 (T+90)
- 4,908 sharesShareKRXDART:20241211000436Canonical exit: 11 Mar 2025 (T+90)
- 2,454 sharesShareKRXDART:20241211000420Canonical exit: 11 Mar 2025 (T+90)
- 196,307 sharesShareKRXDART:20241211000438Canonical exit: 11 Mar 2025 (T+90)
- 2,454 sharesShareKRXDART:20241211000427Canonical exit: 11 Mar 2025 (T+90)
- ShareKRXDART:20241015000377Canonical exit: 9 Jan 2025 (T+90)
- ShareKRXDART:20241015000360Canonical exit: 9 Jan 2025 (T+90)
- ShareKRXDART:20241015000342Canonical exit: 9 Jan 2025 (T+90)
- ShareKRXDART:20241015000346Canonical exit: 9 Jan 2025 (T+90)
- 40,004 sharesKRXDART:20241015000395Canonical exit: 9 Jan 2025 (T+90)
- 74,979 sharesKRXDART:20240912000478Canonical exit: 10 Dec 2024 (T+90)
- ShareKRXDART:20240912000466Canonical exit: 10 Dec 2024 (T+90)
- ShareKRXDART:20240912000438Canonical exit: 10 Dec 2024 (T+90)
25 of 91 declarations
About PharmGen Science, Inc.
Farmgen Science is a company in the health and pharmaceutical sector listed on the XKRX market. It specializes in the development of innovative pharmaceutical solutions.
